▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / IQV

IQV — IQVIA HOLDINGS INC.

—
NYSE · Health Care · Life Sciences Tools & Services · CIK 1478242 ·
Last close
$170.67
Market Cap
$28.48B
52W High
$190.68
52W Low
$154.50
ADV30
1,613,275
Next earnings
2026-07-21
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 4,151,000,000 1,355,000,000 565,000,000 274,000,000 29,675,000,000 1,947,000,000 23,326,000,000
Dec 2025 4,364,000,000 1,436,000,000 651,000,000 514,000,000 29,944,000,000 1,980,000,000 23,314,000,000
Sep 2025 4,100,000,000 1,373,000,000 573,000,000 331,000,000 28,727,000,000 1,814,000,000 22,439,000,000
Jun 2025 4,017,000,000 1,323,000,000 538,000,000 266,000,000 28,632,000,000 2,039,000,000 22,846,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,704,000,000
Investing CF
$-2,196,000,000
Financing CF
$-325,000,000
CapEx
$-588,000,000
Dividends Paid
—
Buybacks
$-1,421,000,000
EPS Diluted TTM
$8.07
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$7,699,000,000
Inventory
—
Receivables
$3,375,000,000
ST Investments
$156,000,000
EBIT TTM
$2,352,000,000
Pretax Income TTM
$1,596,000,000
Interest Exp TTM
$756,000,000
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$16,632,000,512
EBITDA
$3,000,999,936
Free Cash Flow
$2,156,750,080
Enterprise Value
$44,145,471,488
Total Cash
$2,103,000,064
Total Debt
$16,216,999,936
Shares Out
166,900,000
Trailing EPS
$8.04
Book Value
$37.27
ROE
22.5%
ROA
5.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 16,310,000,000 2,287,000,000 1,360,000,000 29,944,000,000 23,314,000,000 — 2,654,000,000
Dec 2024 15,405,000,000 2,269,000,000 1,373,000,000 26,899,000,000 20,832,000,000 — 2,716,000,000
Dec 2023 14,984,000,000 2,061,000,000 1,358,000,000 26,681,000,000 20,569,000,000 — 2,149,000,000
Dec 2022 14,410,000,000 1,827,000,000 1,091,000,000 25,337,000,000 19,572,000,000 — 2,260,000,000

TTM Snapshot

Revenues TTM
$14,503,000,000
NetIncome TTM
$1,210,000,000
OpCashFlow TTM
$0
Assets (Latest)
$26,899,000,000
Forward EPS
$14.20

Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $165.00 · spot: $170.67 · call volume: 213 · put volume: 39
Expected Move to 2026-07-17: ±$25.93 (15.19%) — implied range $144.74 – $196.60 · ATM straddle on $170.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
INCY INCYTE CORP $19.78B $98.99 —
IDXX IDEXX LABORATORIES INC /DE $43.08B $546.09 —
MEDP Medpace Holdings, Inc. $13.05B $457.09 —
ICLR ICON PLC $10.97B $143.27 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $8.78B $182.34 —

News headlines (Yahoo Finance, 1h cache)

Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls
2026-06-17 13:47 · Yahoo
Morgan Stanley favors Charles River Over IQVIA in CRO sector reset
2026-06-17 13:13 · Yahoo
IQVIA (IQV): Buy, Sell, or Hold Post Q1 Earnings?
2026-06-17 09:32 · Yahoo
Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity
2026-06-15 15:12 · Yahoo
Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
2026-06-15 13:00 · Yahoo
2 S&P 500 Stocks Worth Investigating and 1 Facing Headwinds
2026-06-12 11:17 · Yahoo
Q1 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment
2026-06-09 19:26 · Yahoo
Is IQVIA Holdings Stock Outperforming the Dow?
2026-06-09 14:02 · Yahoo
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?
2026-06-08 15:48 · Yahoo
IQVIA Debt Refinance And EPS Upgrade Reshape Long Term Risk Profile
2026-06-06 10:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →